Evaluation efficacy of Azithromycin in prophylaxis of bone marrow transplant complication

Efficacy of Azithromycin in prophylaxis of acute GVHD following allo-SCT in Hematology- oncology research center of shariati Hospital

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT201403281030N16

Enrollment

100

Registered

2014-04-05

Start date

2013-08-23

Completion date

Unknown

Last updated

2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Condition 1: Acute myeloblastic leukaemia. Condition 2: Acute lymphoblastic leukaemia. Condition 3: Chronic myeloid leukaemia. Condition 4: Multiple myeloma. Acute myeloblastic leukaemia Acute lymphoblastic leukaemia Chronic myeloid leukaemia Multiple myeloma

Interventions

Treatment - Drugs

Placebo

Azithromycine 500g orally from day -6 to +12 of transplantation

Placebo 500g orally from day -6 to +12 of transplantation

Intervention 1: Azithromycine 500g orally from day -6 to +12 of transplantation. Intervention 2: Placebo 500g orally from day -6 to +12 of transplantation.

Eligibility

Sex/Gender

All

Age

16 Years to 60 Years

Inclusion criteria

Inclusion criteria: Inclusion criteria: age between 16-60 years old; malignant hematologic disease; allogeneic stem cell transplantation and first stem cell transplantation. Exclusion criteria: age below 16 years old; non malignant disease; second stem cell transplantation.

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
Acute GVHD. Timepoint: Every week till 100 day after transplantation. Method of measurement: Clinical assessment.	—

Secondary

Measure	Time frame
Oral mucositis. Timepoint: Every week till 100 day after transplantation. Method of measurement: Clinical assessment.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactMaryam Barkhordar

Hematology, Oncology and SCT Research Center

maryam.barkhordar@yahoo.com+98 21 8490 2635

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026